ALLIANCE A221805

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Colon, Gastrointestinal, Rectal

Status:

Open

Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study

Eligible for screening study DCP 001

A221805 is reopened to accrual to the Phase III portion with the implementation of Update 5, effective 02/20/24

A221805, Phase II, is closed to accrual effective March 31, 2023, at 4:30 ET.  If interim analysis is positive, Phase III will open to accrual.

A221805-Substudy SI1 is closed to accrual, effective September 15, 2022, at 4:30pm ET.

NCT#04137107